Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis
about
Determinants of Affinity and Proteolytic Stability in Interactions of Kunitz Family Protease Inhibitors with MesotrypsinThe P 2 ′ residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activityAllosteric antibody inhibition of human hepsin proteaseProstate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta.An allosteric anti-hepsin antibody derived from a constrained phage display library.Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells.Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapyFurin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.Membrane-anchored serine proteases in health and disease.Type II transmembrane serine proteases as potential targets for cancer therapy.Biochemical and structural insights into mesotrypsin: an unusual human trypsin.Breaking the epithelial polarity barrier in cancer: the strange case of LKB1/PAR-4High Hepsin expression predicts poor prognosis in Gastric Cancer.Mechanisms of hepatocyte growth factor activation in cancer tissues.Deregulated matriptase activity in oral squamous cell carcinoma promotes the infiltration of cancer-associated fibroblasts by paracrine activation of protease-activated receptor 2.The role of type II transmembrane serine protease-mediated signaling in cancer.Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.Loss of membrane-bound serine protease inhibitor HAI-1 induces oral squamous cell carcinoma cells' invasiveness.Hepatocyte growth factor activator inhibitor type 1 suppresses metastatic pulmonary colonization of pancreatic carcinoma cells.Three-dimensional Structure of a Kunitz-type Inhibitor in Complex with an Elastase-like Enzyme.The Kunitz Domain I of Hepatocyte Growth Factor Activator Inhibitor-2 Inhibits Matriptase Activity and Invasive Ability of Human Prostate Cancer Cells.Analyzing the Type II Transmembrane Serine Protease Hepsin-Dependent Basement Membrane Remodeling in 3D Cell Culture.Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein.Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.
P2860
Q27664637-E21EDE6C-5622-4119-9F0E-F6C549C5F0E7Q27671330-3398B49F-E017-4DD0-8A91-A096DDD5DBCDQ27675904-7ED75C36-D984-4CA7-9CDE-170193165F2FQ30409623-E5B6D41C-B4A2-4F4E-9049-AAC11050EDA3Q34074338-584E2826-8892-4B96-972B-6BD7070DD711Q34132742-BDBAD45E-5F1C-4706-BB01-D64445A5E557Q35095228-53AA4EAE-08DC-40A7-AD4E-C647F0D4A5F5Q35950487-E163BE81-F3FE-46CD-846E-E7EBA1FC2336Q36481769-9DDBD5A2-F608-46A1-895E-4944E96B0CFCQ36969010-C958CA12-C0D8-4E1B-AE7A-D5EEF0C8C966Q37168351-50CAF9F5-48A1-4579-9783-C706C8D20DF6Q37180025-E0E4C60C-51E3-47D2-BF0B-426C9E9AED02Q37204613-99E1E912-B4CA-4BB6-81B4-D8259C4AA5BDQ37411864-993CBE4D-2406-43B5-93E4-1902403EFF9DQ38255480-CA097641-6EFD-456D-865D-58893E8CA4D1Q38746986-3CDF1B2A-7251-4188-A170-3512F47F4667Q39015415-78DC20F0-2E67-4403-AC8F-11DE1E5E91B7Q39326983-34B95D31-FE19-40A4-AA2B-9EF276ADD641Q39409341-BC1AF143-D407-407A-89F0-9F37BB986E9BQ39618840-A53974AF-41DE-48FD-9808-D5D7749BE8A6Q41300593-D572861D-3AA8-4D98-9B0D-6139D5BB57F3Q47171613-5A451B50-7C50-41B4-980B-6B77EC7840F5Q47214955-085C783E-8866-4234-9358-FBC79CF81F46Q49545332-14947736-7513-4AE7-B00B-A97924671B54Q52661781-7A83C4CE-AA41-4867-A688-F2BE5AEFC328
P2860
Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pegylated kunitz domain inhibi ...... ve tumor growth and metastasis
@ast
Pegylated kunitz domain inhibi ...... ve tumor growth and metastasis
@en
Pegylated kunitz domain inhibi ...... ve tumor growth and metastasis
@en-gb
Pegylated kunitz domain inhibi ...... ve tumor growth and metastasis
@nl
type
label
Pegylated kunitz domain inhibi ...... ve tumor growth and metastasis
@ast
Pegylated kunitz domain inhibi ...... ve tumor growth and metastasis
@en
Pegylated kunitz domain inhibi ...... ve tumor growth and metastasis
@en-gb
Pegylated kunitz domain inhibi ...... ve tumor growth and metastasis
@nl
prefLabel
Pegylated kunitz domain inhibi ...... ve tumor growth and metastasis
@ast
Pegylated kunitz domain inhibi ...... ve tumor growth and metastasis
@en
Pegylated kunitz domain inhibi ...... ve tumor growth and metastasis
@en-gb
Pegylated kunitz domain inhibi ...... ve tumor growth and metastasis
@nl
P2093
P3181
P1433
P1476
Pegylated kunitz domain inhibi ...... ve tumor growth and metastasis
@en
P2093
Alvin Gogineni
Bu-Er Wang
Daniel Kirchhofer
Hartmut Koeppen
Mary J C Ludlam
Paul Moran
Racquel Corpuz
Rajkumar Ganesan
Stuart Bunting
Terry Lipari
P304
P3181
P356
10.1158/0008-5472.CAN-09-1995
P407
P577
2009-11-01T00:00:00Z